ATTR-CM is caused by TTR protein build-up in the heart muscle, causing thickening and stiffening of the muscle. Image Credit: Butusova Elena / Shutterstock.

Shanghai-based YolTech Therapeutics has dosed the first patient with YOLT-201 in the Phase I trial evaluating the therapy as a treatment for hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

The open-label Phase I trial (NCT06082050) will assess the therapy’s safety, tolerability, pharmacokinetics, and pharmacodynamics. The study will also aim to identify an optimal biologically active dose.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A genetic mutation of the gene for transthyretin (TTR) protein causes ATTR, which leads to the production of an abnormal form of the protein causing protein build-up in the organs. ATTR-CM is caused by TTR protein build-up in the heart muscle causing thickening and stiffening of the muscle. This impairs the heart’s ability to function properly and can lead to stroke or death.

YOLT-201 is an in vivo genome editing candidate which consists of lipid nanoparticles (LNP), formed with ionisable lipids as primary excipients to encapsulate messenger ribonucleic acid (mRNA) and single guide RNA (sgRNA) raw materials. The sgRNA component is responsible for preventing transcription of the TTR gene, as such stopping the production of the TTR protein.

ATTR-CM treatment landscape

Multiple companies are developing therapies for ATTR-CM. One of the more clinically advanced therapy programmes includes Alnylam Pharmaceuticals’s Onpattro (patisiran).

The Phase III trial (NCT03997383) for the RNA interference (RNAi) therapy met its primary endpoint but despite positive results, the US Food and Drug Administration (FDA) refused to approve the therapy. In October, the agency issued a complete response letter (CRL) stating that the drug “could not be approved in its present form”. Following the CRL, Alnylam stated that it would no longer seek US approval for the therapy in ATTR-CM indication.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ionis Pharmaceutical’s antisense therapy eplontersen is being evaluated in a Phase III trial (NCT04136171). The placebo-controlled study enrolled more than 1,400 participants, with data expected in H1 2025.

Eplontersen is being developed as part of a development and commercialisation agreement with AstraZeneca. The companies are also seeking FDA approval for the therapy as a treatment of transthyretin-mediated amyloid polyneuropathy. The Prescription Drug User Fee Act (PDUFA) action date for the approval was set for 22 December 2023.

The early clinical stage therapies being developed to treat ATTR-CM include Intellia Therapeutics and Regeneron Pharmaceuticals’ CRISPR/Cas9 genome editing therapy NTLA-2001. The therapy is currently in Phase I trial (NCT04601051). Neurimmune’s monoclonal antibody therapy NI006 demonstrated a positive safety profile in the Phase I trial. NI006 is being developed in partnership with AstraZeneca.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva. 

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.